Paroxetine Oral Tablets (Immediate-Release) Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets (immediate-release)
Available Strengths: 10 mg, 20 mg, 30 mg, 40 mg
Reference Brands: US: Paxil®, Pexeva®, Brisdelle®; EU: Seroxat®, ParoMerck®, Paxetin®
Category:
Antipsychotropic Drugs
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that works by increasing serotonin levels in the brain to enhance mood and reduce anxiety. It is used to treat depression, panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, PTSD, and social anxiety, promoting emotional stability and mental well-being.
Paroxetine Oral Tablets (immediate-release) is available in Oral Tablets (immediate-release)
and strengths such as 10 mg, 20 mg, 30 mg, 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Paroxetine Oral Tablets (immediate-release) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Paroxetine Oral Tablets (immediate-release) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Paroxetine immediate-release tablets are FDA-approved in the USA for depression, panic disorder, OCD, PTSD, GAD, and social anxiety disorder. As a selective serotonin reuptake inhibitor (SSRI), it carries a Boxed Warning regarding increased risk of suicidal thoughts in adolescents and young adults. Regulatory oversight includes strict GMP compliance, labeling requirements, and pharmacovigilance obligations, including adverse event reporting. In the EU, paroxetine IR tablets are widely approved by national authorities and/or the EMA for similar indications. Regulatory submissions must include RMPs, PSURs, and quality documentation. Discover global suppliers and compliant dossiers at Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing